Patients with diabetes mellitus type II (DM II) benefit from glibenclamide treatment, which inhibits KATP (Sur1-Kir6.2) channels in pancreatic β islet cells and leads to increased insulin release [2,3,4,5]. This evidence concerns the gene INS and type 2 diabetes mellitus.